Prognostic and Clinicopathological Value of PD-L1 in Melanoma: A Meta-Analysis
- 1 June 2020
- journal article
- research article
- Published by Elsevier in The American Journal of the Medical Sciences
- Vol. 359 (6) , 339-346
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (81872047)
- National Natural Science Foundation of China (81572430)
This publication has 36 references indexed in Scilit:
- Up-Regulation of PD-L1, IDO, and T regs in the Melanoma Tumor Microenvironment Is Driven by CD8 + T CellsScience Translational Medicine, 2013
- Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunityCurrent Opinion in Immunology, 2012
- Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune EscapeScience Translational Medicine, 2012
- PD‐1 expression on Melan‐A‐reactive T cells increases during progression to metastatic diseaseInternational Journal of Cancer, 2011
- Overall survival and PD‐L1 expression in metastasized malignant melanomaCancer, 2010
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Tumor cell expression of programmed cell death‐1 ligand 1 is a prognostic factor for malignant melanomaCancer, 2010
- Surgery and radiotherapy in the treatment of cutaneous melanomaAnnals of Oncology, 2009
- PD-1 and Its Ligands in Tolerance and ImmunityAnnual Review of Immunology, 2008
- Activation-Induced Expression of Human Programmed Death-1 Gene in T-LymphocytesExperimental Cell Research, 1997